clinical trial · NCT07570654
Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
COMPASS Pathways·phase3·recruiting·n = 300
PTSD - Post Traumatic Stress DisorderPTSDPTSD SymptomsPTSD, Post Traumatic Stress DisorderCOMP360 psilocybin
brief summary
The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder (PTSD) symptoms when administered alongside monitoring and support from a trained study team. COMP360 is a lab-made form of the naturally occurring chemical compound psilocybin.
started
Sep 1, 2026
primary completion
Nov 1, 2028
completion
Sep 1, 2029
last updated
Oct 21, 2026
official title
A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol